OBI received notice from patent attorney’s office that product patent for OBI-3424 named “DNA alkylating agents” has been approved by IP Australia

  1. Date of occurrence of the event: Aug 15, 2018
  2. Company name: OBI Pharma Inc.
  3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office
  4. Reciprocal shareholding ratios: N/A
  5. Cause of occurrence: OBI received notice from patent attorney’s office that product patent for OBI-3424 named “DNA alkylating agents” has been approved by IP Australia (No. 2016229136).
  6. Countermeasures: None
  7. Any other matters that need to be specified: None